A novel peptide interferes with Mycobacterium tuberculosis virulence and survival.

ABSTRACT: Tuberculosis (TB) is a huge global burden, with new and resistant strains emerging at an alarming rate, necessitating an urgent need for a new class of drug candidates. Here, we report that SL3, a novel 33-amino acid peptide, causes debilitating effects on mycobacterial morphology. Treatment with SL3 drastically inhibits the growth of Mycobacterium tuberculosis in vitro as well as in a pre-clinical mouse model for M.tb infection. Microarray analysis of SL3-expressing strain demonstrates wide-scale transcriptional disruption in M.tb. We therefore believe that SL3 and similar peptides may herald a new approach towards discovering new molecules for TB therapy.

SUBMITTER: Samuchiwal SK 

PROVIDER: S-EPMC4208091 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature